特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

経皮ドラッグデリバリーシステムの世界市場 (~2023年):パッチ・半固形製剤

Transdermal Drug Delivery System Market by Type (Patches and Semisolid formulations), Applications (Pain Management, Central Nervous System Disorders, Hormonal Applications, Cardiovascular Diseases), End User, and Region - Global Forecast to 2023

発行 MarketsandMarkets 商品コード 769379
出版日 ページ情報 英文 134 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.59円で換算しております。
経皮ドラッグデリバリーシステムの世界市場 (~2023年):パッチ・半固形製剤 Transdermal Drug Delivery System Market by Type (Patches and Semisolid formulations), Applications (Pain Management, Central Nervous System Disorders, Hormonal Applications, Cardiovascular Diseases), End User, and Region - Global Forecast to 2023
出版日: 2019年01月08日 ページ情報: 英文 134 Pages
概要

経皮ドラッグデリバリーシステムの市場は予測期間中4.5%のCAGR (複合年間成長率) で推移し、2018年の57億米ドルから、2023年には71億米ドルの規模に成長すると予測されています。同市場の成長は慢性疾患の罹患率の世界的な増加によって推進されており、今後は技術的進歩が市場の成長を支えると予測されています。

当レポートでは、世界の経皮ドラッグデリバリーシステムの市場を調査し、市場およびシステムの概要、市場成長への各種影響因子および市場機会の分析、製品タイプ・用途・エンドユーザー・地域/主要国別の動向と市場規模の推移と予測、競合環境、主要企業のプロファイルをまとめています。

FIGURE 12 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET

第1章 イントロダクション

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場力学

  • イントロダクション
  • 市場力学
    • 成長推進因子
    • 成長抑制因子
    • 市場機会
    • 課題

第6章 世界の経皮ドラッグデリバリーシステム市場:タイプ別

  • イントロダクション
  • 経皮パッチ
    • DIA (DRUG-IN-ADHESIVE) パッチ
    • マトリックスパッチ
    • リザーバーメンブレンパッチ
    • マイクロニードルパッチ
  • 経皮半固体剤
    • ゲル
    • 軟膏
    • スプレー

第7章 世界の経皮ドラッグデリバリーシステム市場:用途別

  • イントロダクション
  • 疼痛管理
  • ホルモン療法
    • テストステロン補充療法
    • 経皮エストロゲン療法
  • 中枢神経系疾患
  • 心臓血管疾患
  • その他

第8章 世界の経皮ドラッグデリバリーシステム市場:エンドユーザー別

  • イントロダクション
  • 在宅ケア
  • 病院・診療所

第9章 世界の経皮ドラッグデリバリーシステム市場:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第10章 競合環境

  • 概要
  • 市場シェア分析
  • 競合シナリオ

第11章 企業プロファイル

  • 久光製薬
  • MYLAN N.V.
  • UCB S.A.
  • NOVARTIS AG
  • GLAXOSMITHKLINE PLC
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • JOHNSON & JOHNSON (J&J)
  • ENDO INTERNATIONAL, INC.
  • PURDUE PHARMA L.P.
  • LAVIPHARM
  • LEAD CHEMICALS CO., INC.
  • LUYE PHARMA GROUP

第12章 付録

図表

LIST OF TABLES

  • TABLE 1: COMPARISON BETWEEN TRANSDERMAL PATCHES AND TRANSDERMAL SEMISOLID FORMULATIONS
  • TABLE 2: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 3: TRANSDERMAL PATCHES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 4: TRANSDERMAL PATCHES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 5: TRANSDERMAL SEMISOLIDS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 6: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 7: TRANSDERMAL DRUG DELIVERY SYSTEMS AVAILABLE FOR PAIN MANAGEMENT
  • TABLE 8: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 9: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET FOR HORMONAL APPLICATIONS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 10: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET FOR HORMONAL APPLICATIONS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 11: TRANSDERMAL DRUG DELIVERY SYSTEMS AVAILABLE FOR TESTOSTERONE REPLACEMENT THERAPY
  • TABLE 12: TRANSDERMAL DRUG DELIVERY SYSTEMS AVAILABLE FOR TRANSDERMAL ESTROGEN THERAPY
  • TABLE 13: TRANSDERMAL DRUG DELIVERY SYSTEMS AVAILABLE FOR CENTRAL NERVOUS SYSTEM DISORDERS
  • TABLE 14: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 15: TRANSDERMAL DRUG DELIVERY SYSTEMS AVAILABLE FOR CARDIOVASCULAR DISEASES
  • TABLE 16: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 17: TRANSDERMAL DRUG DELIVERY SYSTEMS AVAILABLE FOR OTHER APPLICATIONS
  • TABLE 18: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 19: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 20: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 21: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 22: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 23: NORTH AMERICA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 24: NORTH AMERICA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 25: NORTH AMERICA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 26: NORTH AMERICA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 27: US: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 28: US: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 29: US: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 30: CANADA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 31: CANADA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 32: CANADA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 33: DEVELOPMENTS IN THE FIELD OF TDDS IN EUROPE, 2015-2018
  • TABLE 34: EUROPE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 35: EUROPE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 36: EUROPE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 37: EUROPE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 38: GERMANY: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 39: GERMANY: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 40: GERMANY: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 41: UK: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 42: UK: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 43: UK: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 44: FRANCE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 45: FRANCE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 46: FRANCE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 47: ROE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 48: ROE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 49: ROE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 50: ASIA PACIFIC: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 51: ASIA PACIFIC: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 52: ASIA PACIFIC: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 53: ASIA PACIFIC: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 54: JAPAN: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 55: JAPAN: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 56: JAPAN: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 57: CHINA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 58: CHINA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 59: CHINA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 60: INDIA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 61: INDIA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 62: INDIA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 63: ROAPAC: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 64: ROAPAC: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 65: ROAPAC: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 66: ROW: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 67: ROW: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 68: ROW: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 69: PRODUCT LAUNCHES AND APPROVALS
  • TABLE 70: EXPANSIONS
  • TABLE 71: AGREEMENTS AND COLLABORATIONS

LIST OF FIGURES

  • FIGURE 1: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SEGMENTATION
  • FIGURE 2: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET: RESEARCH METHODOLOGY
  • FIGURE 3: RESEARCH DESIGN
  • FIGURE 4: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5: MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
  • FIGURE 6: MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 7: DATA TRIANGULATION METHODOLOGY
  • FIGURE 8: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2018
  • FIGURE 9: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2018
  • FIGURE 10: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2018
  • FIGURE 11: GEOGRAPHIC SNAPSHOT: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET
  • FIGURE 12: INCREASE IN THE PREVALENCE OF CHRONIC DISEASES AND TECHNOLOGICAL ADVANCEMENTS ARE KEY FACTORS DRIVING THE GROWTH OF THE MARKET
  • FIGURE 13: TRANSDERMAL PATCHES TO DOMINATE THE TRANSDERMAL DRUG DELIVERY SYSTEMS IN NORTH AMERICAN MARKET DURING THE FORECAST PERIOD
  • FIGURE 14: TRANSDERMAL PATCHES TO DOMINATE THE TRANSDERMAL DRUG DELIVERY SYSTEMS IN NORTH EUROPEAN MARKET DURING THE FORECAST PERIOD
  • FIGURE 15: JAPAN IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 16: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
  • FIGURE 17: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2018 VS. 2023 (USD MILLION)
  • FIGURE 18: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2018 VS. 2023 (USD MILLION)
  • FIGURE 19: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2018 VS. 2023 (USD MILLION)
  • FIGURE 20: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY REGION, 2018 VS. 2023
  • FIGURE 21: NORTH AMERICA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SNAPSHOT
  • FIGURE 22: EUROPE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SNAPSHOT
  • FIGURE 23: ASIA PACIFIC: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SNAPSHOT
  • FIGURE 24: ROW: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SNAPSHOT
  • FIGURE 25: KEY DEVELOPMENTS IN THE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET (2015-2018)
  • FIGURE 26: MARKET SHARE ANALYSIS BY KEY PLAYERS (2015-2018)
  • FIGURE 27: HISAMITSU PHARMACEUTICAL: COMPANY SNAPSHOT (2017)
  • FIGURE 28: MYLAN: COMPANY SNAPSHOT (2017)
  • FIGURE 29: UCB: COMPANY SNAPSHOT (2017)
  • FIGURE 30: NOVARTIS: COMPANY SNAPSHOT (2017)
  • FIGURE 31: GSK: COMPANY SNAPSHOT (2017)
  • FIGURE 32: BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2017)
  • FIGURE 33: JOHNSON & JOHNSON: COMPANY SNAPSHOT (2017)
  • FIGURE 34: ENDO INTERNATIONAL: COMPANY SNAPSHOT (2017)
  • FIGURE 35: LUYE PHARMA: COMPANY SNAPSHOT (2017)
目次
Product Code: MD 6846

"The transdermal drug delivery systems market is projected to grow at a CAGR of 4.5% during the forecast period."

The transdermal drug delivery systems market is expected to reach 7.1 billion by 2023 from an estimated USD 5.7 billion in 2018, at a CAGR of 4.5% during the forecast period. Market growth is largely driven by the global increase in the prevalence of chronic diseases. In addition, technological advancements in transdermal drug delivery systems are expected to support market growth in the coming years. However, drug failures and recalls of transdermal drug delivery systems are expected to restrain market growth to a certain extent.

By application, the pain management segment is expected to grow at the highest rate during the forecast period.

On the basis of application, the transdermal drug delivery systems market is segmented into five broad categories-pain management, central nervous system disorders, hormonal applications, cardiovascular diseases, and other applications (smoking cessation, motion sickness, and overactive bladder treatment). The pain management segment is expected to grow at the highest CAGR during the forecast period owing to the high burden of chronic pain worldwide and the growing availability of transdermal products for pain management.

The transdermal patches segment is expected to dominate the market in 2018.

On the basis of type, the transdermal drug delivery systems market is segmented into transdermal patches and transdermal semisolids. In 2018, the transdermal patches segment is expected to account for a dominant share of the transdermal drug delivery systems market. This drug delivery system offers several advantages, such as reduced dosing frequency, improved bioavailability, reduced adverse events, and drug input termination at any point by the removal of the patch. Also, the use of patches results in increased patient compliance due to their non-invasive nature and painless application. These factors are expected to drive market growth.

The North American transdermal drug delivery systems market is expected to grow at the highest CAGR during the forecast period.

North America, comprising the US and Canada, offers high-growth opportunities for players in the transdermal drug delivery systems market. This segment is slated to register the highest CAGR during the forecast period. Some of the factors driving market growth in the North American region are rising prevalence of targeted diseases (such as chronic pain, central nervous system disorders, and cardiovascular diseases) in the region, the increasing use of contraceptives, and the increasing number of research activities related to transdermal drug delivery systems.

Break of primary participants was as mentioned below:

  • By Company Type - Tier 1-55%, Tier 2-25% and Tier 3-20%
  • By Designation - C-level-43%, Director Level-32%, Others-25%
  • By Region - North America-38%, Europe-29%, Asia Pacific-23%, RoW-10%

The key players in the transdermal drug delivery systems market are: Hisamitsu Pharmaceutical (Japan), Mylan (US), UCB (Belgium), Novartis (Switzerland), GlaxoSmithKline (UK), Boehringer Ingelheim (Germany), Johnson & Johnson (US), Endo International (Ireland), and Purdue Pharma (US).

Research Coverage:

The report analyzes the transdermal drug delivery systems market and aims at estimating the market size and future growth potential of this market based on various segments such as applications, type, end user, and region. The report also includes competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report:

The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them garner a greater share. Firms purchasing the report could use one, or a combination of the below mentioned five strategies.

This report provides insights into the following pointers:

  • Market Penetration: Comprehensive information on the services offered by the top players in the transdermal drug delivery systems market. The report analyzes the market based on applications, type, end user, and region
  • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the transdermal drug delivery systems market
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various transdermal drug delivery systems solutions across regions
  • Market Diversification: Exhaustive information about solutions and services, untapped regions, recent developments, and investments in the transdermal drug delivery systems market
  • Competitive Assessment: In-depth assessment of market shares, strategies, distribution networks, and manufacturing capabilities of the leading players in the market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH DATA
    • 2.1.1. SECONDARY DATA
      • 2.1.1.1. Key Data from Secondary Sources
    • 2.1.2. PRIMARY DATA
      • 2.1.2.1. Key Data from Primary Sources
      • 2.1.2.2. Key Industry Insights
  • 2.2. MARKET SIZE ESTIMATION
    • 2.2.1. MARKET DATA VALIDATION AND TRIANGULATION
  • 2.3. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET OVERVIEW
  • 4.2. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2018
  • 4.3. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2018
  • 4.4. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET: GEOGRAPHIC SNAPSHOT

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. DRIVERS
      • 5.2.1.1. Increasing prevalence of chronic diseases
      • 5.2.1.2. Technological advancements in transdermal drug delivery systems
    • 5.2.2. RESTRAINTS
      • 5.2.2.1. Drug failure and recalls of transdermal drug delivery systems
    • 5.2.3. OPPORTUNITIES
      • 5.2.3.1. Collaborations between pharmaceutical companies and drug delivery firms
      • 5.2.3.2. Self-administration and home care drug delivery systems
    • 5.2.4. CHALLENGES
      • 5.2.4.1. Technical barriers related to skin irritation and permeability

6. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE

  • 6.1. INTRODUCTION
  • 6.2. TRANSDERMAL PATCHES
    • 6.2.1. DRUG-IN-ADHESIVE PATCHES
    • 6.2.2. MATRIX PATCHES
    • 6.2.3. RESERVOIR MEMBRANE PATCHES
    • 6.2.4. MICRONEEDLE PATCHES
  • 6.3. TRANSDERMAL SEMISOLIDS
    • 6.3.1. GELS
    • 6.3.2. OINTMENTS
    • 6.3.3. SPRAYS

7. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION

  • 7.1. INTRODUCTION
  • 7.2. PAIN MANAGEMENT
    • 7.2.1. PAIN MANAGEMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET
  • 7.3. HORMONAL APPLICATIONS
    • 7.3.1. TESTOSTERONE REPLACEMENT THERAPY
      • 7.3.1.1. Skin irritation, poor absorption of drugs, high costs, and the need for frequent dosing are factors limiting market growth
    • 7.3.2. TRANSDERMAL ESTROGEN THERAPY
      • 7.3.2.1. Growing use of transdermal contraceptive patches is likely to drive the market for transdermal estrogen therapy
  • 7.4. CENTRAL NERVOUS SYSTEM DISORDERS
    • 7.4.1. INCREASING INCIDENCE OF PARKINSON'S AND ALZHEIMER'S DISEASE TO DRIVE THE MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS
  • 7.5. CARDIOVASCULAR DISEASES
    • 7.5.1. AVAILABILITY OF ALTERNATIVE AND ADVANCED DRUG DELIVERY OPTIONS TO LIMIT MARKET GROWTH
  • 7.6. OTHER APPLICATIONS
    • 7.6.1. INCREASING DEMAND FOR ADVANCED TRANSDERMAL MICRONEEDLE PATCHES FOR DIABETES MANAGEMENT-A KEY MARKET DRIVER

8. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER

  • 8.1. INTRODUCTION
  • 8.2. HOME CARE SETTINGS
  • 8.3. HOSPITALS & CLINICS

9. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY REGION

  • 9.1. INTRODUCTION
  • 9.2. NORTH AMERICA
    • 9.2.1. US
      • 9.2.1.1. Rising prevalence of targeted disease and development of technologically advanced transdermal drug delivery systems-key factors driving market growth
    • 9.2.2. CANADA
      • 9.2.2.1. Rising prevalence of chronic diseases and funding for the development of transdermal drug delivery systems to drive market growth
  • 9.3. EUROPE
    • 9.3.1. GERMANY
      • 9.3.1.1. Growing focus of pharmaceutical companies in Germany on the development of transdermal products to drive market growth
    • 9.3.2. UK
      • 9.3.2.1. Increasing funding for the R&D of innovative transdermal technologies to drive market growth
    • 9.3.3. FRANCE
      • 9.3.3.1. Development of transdermal drug delivery systems by local players to support market growth
    • 9.3.4. ROE
  • 9.4. ASIA PACIFIC
    • 9.4.1. JAPAN
      • 9.4.1.1. Increasing number of product approvals and growing focus of local players on R&D of transdermal systems to support market growth
    • 9.4.2. CHINA
      • 9.4.2.1. Growing focus of major players in China towards the development of transdermal drug delivery systems to drive market growth
    • 9.4.3. INDIA
      • 9.4.3.1. Growing awareness among healthcare providers and patients and increasing focus on noninvasive methods of drug delivery to drive market growth
    • 9.4.4. ROPAC
  • 9.5. ROW

10. COMPETITIVE LANDSCAPE

  • 10.1. OVERVIEW
  • 10.2. MARKET SHARE ANALYSIS
  • 10.3. MARKET SHARE ANALYSIS, BY APPLICATION
    • 10.3.1. PAIN MANAGEMENT
    • 10.3.2. HORMONAL APPLICATIONS
    • 10.3.3. CENTRAL NERVOUS SYSTEM DISORDERS
    • 10.3.4. CARDIOVASCULAR DISEASES
  • 10.4. COMPETITIVE SCENARIO
    • 10.4.1. PRODUCT LAUNCHES AND APPROVALS
    • 10.4.2. EXPANSIONS
    • 10.4.3. AGREEMENTS AND COLLABORATIONS
    • 10.4.4. ACQUISITIONS

11. COMPANY PROFILES (Business overview, Products offered, Recent Developments, MNM view)*

  • 11.1. HISAMITSU PHARMACEUTICAL CO., INC.
  • 11.2. MYLAN N.V.
  • 11.3. UCB S.A.
  • 11.4. NOVARTIS AG
  • 11.5. GLAXOSMITHKLINE PLC
  • 11.6. BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • 11.7. JOHNSON & JOHNSON (J&J)
  • 11.8. ENDO INTERNATIONAL, INC.
  • 11.9. PURDUE PHARMA L.P.
  • 11.10. LAVIPHARM
  • 11.11. LEAD CHEMICALS CO., INC.
  • 11.12. LUYE PHARMA GROUP

*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

12. APPENDIX

  • 12.1. DISCUSSION GUIDE
  • 12.2. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3. AVAILABLE CUSTOMIZATIONS
  • 12.4. RELATED REPORTS
  • 12.5. AUTHOR DETAILS